Dr. Tim Sayed opens with a published personal account from a 56-year-old runner and author who had saline implants placed in the early 2000s and chose, two decades later, to have them removed and stay flat. The story moves through familiar territory for explant patients — the original decision made from insecurity, the body changes that followed breastfeeding, the capsular contracture that eventually developed, and the years it took to arrive at a choice that felt genuinely her own. Sayed doesn't frame the original augmentation as a mistake, but he is candid about how often external pressure — cultural, familial, sometimes from a partner — shapes these decisions in ways patients don't fully recognize at the time. He reflects on why pre-surgical counseling matters, and why the question of motivation deserves more attention than it typically gets in a cosmetic surgery context.

The conversation also touches on a newly launched device, the Explant Express from Applied Medical Technology, a suction retrieval system designed to help surgeons manage ruptured implants during removal more cleanly. Sayed explains the real surgical challenge it's meant to address — silicone containment when the capsule tears — and notes he hasn't used it yet, but sees a plausible role for it in known rupture cases.

What runs underneath both segments is the same honest question: what does it actually mean to accept your body as it is, and how long does that usually take.

Contact Dr. Tim Sayed:
Phone: (858) 247-2933
Email: [email protected]
Website: timsayedmd.com
Instagram: @timsayedmd
YouTube: @Timsayedmd
Facebook: Tim Sayed MD

Dr. Tim Sayed takes a closer look at the latest shift in medically supervised weight loss with the FDA approval of an oral GLP-1 medication. After years of injections dominating the space, a once daily pill introduces a new layer of accessibility, convenience, and patient choice.

He walks through how these medications actually work in the body, from slowing gastric emptying to quieting food noise, and why they’ve been so impactful for patients struggling with weight loss. The conversation stays grounded in real-world considerations, including affordability, insurance access, and the role compounding pharmacies have played as demand surged.

There’s also a thoughtful comparison between competing medications, looking at effectiveness, side effects, and what really matters when deciding between options. Questions around long term use, maintenance, and sustainability are part of the reality, not something to gloss over.

It’s not about hype or quick fixes. It’s about understanding what’s changing, what’s promising, and what still requires careful consideration as this space continues to evolve.

Contact Dr. Tim Sayed:
Phone: (858) 247-2933
Email: [email protected]
Website: timsayedmd.com
Instagram: @timsayedmd
YouTube: @Timsayedmd
Facebook: Tim Sayed MD

Dr. Tim Sayed takes a thoughtful look at newly published data from the Achieve 3 trial, a 52-week head-to-head study comparing Eli Lilly’s investigational oral GLP-1, orforglipron, to oral semaglutide in adults with type 2 diabetes not adequately controlled on metformin.

Published in The Lancet, the study showed greater A1C reduction and more weight loss at higher doses of orforglipron, with improvements appearing as early as four weeks and sustained through the full year. Participants also saw clinically meaningful changes in cardiovascular risk markers, including non-HDL cholesterol, HDL, triglycerides, and systolic blood pressure.

Dr. Sayed walks through how the trial was structured, what the numbers actually represent, and what to make of the higher rates of gastrointestinal side effects seen with the more potent dosing. He reflects on what it takes for a medication to move through phase three trials and toward FDA review, and why that rigor matters.

From practical issues like dosing and food restrictions to the broader landscape of compounding pharmacies and evolving GLP-1 access, this is a grounded conversation about where the science stands and what may be coming next.

Contact Dr. Tim Sayed:
Phone: (858) 247-2933
Email: [email protected]
Website: timsayedmd.com
Instagram: @timsayedmd
YouTube: @Timsayedmd
Facebook: Tim Sayed MD

On The Scalpel’s Edge, Dr. Tim Sayed takes a clear-eyed look at where GLP-1 weight loss medications are headed and why the landscape feels so unsettled right now.

From the FDA’s latest move against compounded GLP-1 drugs to the rise of direct-to-consumer platforms and the new TrumpRX pricing model, this is an honest, surgeon-level reflection on access, affordability, and control. Dr. Sayed shares how these shifts affect real patients, real practices, and the expectations around weight loss, plastic surgery, and long-term health.

It’s a grounded conversation about what’s changing, what may disappear, and what still matters when medicine, regulation, and patient care collide.

Contact Dr. Tim Sayed:
Phone: (858) 247-2933
Email: [email protected]
Website: timsayedmd.com
Instagram: @timsayedmd
YouTube: @Timsayedmd
Facebook: Tim Sayed MD

Dr. Tim Sayed walks through some recent developments in the GLP-1 space that raise a question almost everyone on these medications eventually asks. What happens when you stop. He reflects on new data around weight regain after discontinuing GLP-1 drugs, including a large meta-analysis showing how quickly weight and metabolic markers tend to return toward baseline once the medication is stopped.

He also breaks down early clinical data on an endoscopic procedure called Revita that aims to support weight maintenance after GLP-1 discontinuation by targeting the duodenum. The discussion stays grounded in real numbers, practical tradeoffs, and the lived reality of patients weighing long term injections versus invasive but one-time interventions.

Along the way, Dr. Sayed addresses cost, insurance gaps, emerging alternatives, and why maintenance is likely the real long-term conversation with GLP-1 therapy. The tone is thoughtful, measured, and honest about both the promise and the limits of current options.

Contact Dr. Tim Sayed:
Phone: (858) 247-2933
Email: [email protected]
Website: timsayedmd.com
Instagram: @timsayedmd
YouTube: @Timsayedmd
Facebook: Tim Sayed MD

On The Scalpel’s Edge, Dr. Tim Sayed talks with Elizabeth Everett about her experience with breast implant illness and what it was like to spend years feeling dismissed while her body kept sending louder and louder signals. She shares why she chose implants after having her third son, how symptoms slowly built over time, and the way stress, hormones, and a foreign body in her system seemed to create a perfect storm.

Elizabeth walks through the health changes that pushed her to keep searching for answers, the relief of finally hearing a doctor say “you are not crazy,” and what the explant surgery revealed once she was opened up. They also talk honestly about how invalidation can damage mental health, why the breast implant illness conversation gets so polarized, and what it means to find self trust again while your body heals in stages.

The conversation stays grounded in the reality that recovery can be a longer process, with small wins that add up over months, and it ends with a simple message Elizabeth wishes more women heard sooner: listen to your body, keep advocating for yourself, and know there is help and hope.

Contact Dr. Tim Sayed:
Phone: (858) 247-2933
Email: [email protected]
Website: timsayedmd.com
Instagram: @timsayedmd
YouTube: @Timsayedmd
Facebook: Tim Sayed MD

In this episode of The Scalpel’s Edge, Dr. Tim Sayed takes a deep dive into the latest research on GLP1 medications and the lesser known side effects patients may experience. Drawing from new studies, clinical insights, and his own experience with GLP1 therapy, Dr. Sayed breaks down how these medications may influence anemia risk, micronutrient deficiencies, appetite changes, and overall metabolic health.

He also explores new data on hemoglobin changes, iron intake, B12 levels, and nutritional patterns seen in GLP1 users. Dr. Sayed reviews current guidance for assessing risk, monitoring labs, and supporting patients through evidence-informed nutritional strategies. The episode closes with an important discussion on tapering and discontinuation, highlighting why there is still no standardized exit plan and how physicians can work with patients to navigate the evolving landscape of GLP1 treatment.

Tune in for a grounded, practical, and insightful conversation on optimizing health while using GLP1s.

Contact Dr. Tim Sayed:
Phone: (858) 247-2933
Email: [email protected]
Website: timsayedmd.com
Instagram: @timsayedmd
YouTube: @Timsayedmd
Facebook: Tim Sayed MD

In this episode of The Scalpel’s Edge, Dr. Tim Sayed takes listeners inside the world of personalized genetic testing and how it can transform perioperative planning for explant patients and anyone seeking deeper insight into their inflammatory health.

Dr. Sayed breaks down the SHARP program’s integrated approach, which combines genomic testing, supplements, psychological support, and lifestyle guidance to help patients understand their unique risks, strengths, and metabolic tendencies. Using his own recent lab results as an example, he explores everything from detoxification pathways and heavy metal sensitivity to sleep quality, cardiovascular markers, skin aging, nutritional tendencies, and pharmacogenomics.

Whether you are considering breast implant removal, navigating chronic inflammation, or simply curious about how genetic data can optimize your wellness, this episode offers a clear look at how these tests work, why they matter, and how they can guide safer, more personalized care.

Contact Dr. Tim Sayed:
Phone: (858) 247-2933
Email: [email protected]
Website: timsayedmd.com
Instagram: @timsayedmd
YouTube: @Timsayedmd
Facebook: Tim Sayed MD

Explore the growing movement of breast implant removal as Dr. Tim Sayed breaks down why twenty four well known celebrities decided to explant. In this powerful episode of The Scalpel’s Edge, Dr. Sayed explains the emotional, physical, and aesthetic reasons behind their decisions and highlights the rising awareness around breast implant illness, autoimmune symptoms, and personal identity. He also shares insights from his double board certified surgical practice, where he focuses on explant surgery and holistic wellness.
 

Join this deep dive into transparency, healing, and patient empowerment as Dr. Sayed walks through each celebrity story and the lessons they offer for anyone considering implant removal.

Contact Dr. Tim Sayed:
Phone: (858) 247-2933
Email: [email protected]
Website: timsayedmd.com
Instagram: @timsayedmd
YouTube: @Timsayedmd
Facebook: Tim Sayed MD

A new era of weight management is on the horizon. In this episode of The Scalpel’s Edge, learn how oral GLP-1 medications like semaglutide (Rebelsus) are changing the landscape of obesity care and cardiovascular health. Explore key findings from the OASIS-4 Phase 3 trial, new FDA updates, and what the data reveals about blood sugar control, heart health, and weight reduction across all age groups. Discover why oral options may soon rival injectables like Ozempic, Wegovy, and Mounjaro—and what this means for the millions of people seeking sustainable wellness solutions.

Contact Dr. Tim Sayed:
Phone: (858) 247-2933
Email: [email protected]
Website: timsayedmd.com
Instagram: @timsayedmd
YouTube: @Timsayedmd
Facebook: Tim Sayed MD